Estimated Read Time:

1 minute

SABCS Snippets: Beyond CDK4/6 Inhibitors

SABCS Program Director Kate Lathrop, MD, talks with Shom Goel, MBBS, PhD, about CDK4/6 inhibitors and emerging options to advance treatment for HR-positive, HER-negative metastatic breast cancer.

Share

Recent Posts